MedTrace Logo

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06533644 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2026-05-18

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

Conditions

Interventions

PROCEDURE

Partial Oncolysis

Partial tumor oncolysis will be completed by cryolysis.

DRUG

SV-102

Intratumoral infusion of SV-102

Sponsors & Collaborators

  • Syncromune, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen Dale, MD · Syncromune, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-29
Primary Completion
2028-04-14
Completion
2028-04-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533644 on ClinicalTrials.gov